Cargando…
Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review
Antiphospholipid syndrome (APS) is a hypercoagulation condition associated with the incidence of heterogenic antiphospholipid antibodies (aPLs), which non-specifically affect hemostasis processes. APS is clinically manifested by recurrent arterial and venous thromboses and reproduction losses. The a...
Autores principales: | Bradacova, Pavla, Slavik, Ludek, Ulehlova, Jana, Skoumalova, Adela, Ullrychova, Jana, Prochazkova, Jana, Hlusi, Antonin, Manukyan, Gayane, Kriegova, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914732/ https://www.ncbi.nlm.nih.gov/pubmed/33567576 http://dx.doi.org/10.3390/biomedicines9020166 |
Ejemplares similares
-
Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome
por: Bradáčová, Pavla, et al.
Publicado: (2022) -
17β-Estradiol Promotes Proinflammatory and Procoagulatory Phenotype of Innate Immune Cells in the Presence of Antiphospholipid Antibodies
por: Manukyan, Gayane, et al.
Publicado: (2020) -
Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro
por: Manukyan, Gayane, et al.
Publicado: (2020) -
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021) -
Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the
Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
por: Slavik, L., et al.
Publicado: (2019)